Bitopertin (R enantiomer) is a non-competitive glycine reuptake (GlyT1) inhibitor with potential therapeutic applications in neurological and psychiatric disorders, particularly as a modulator of NMDA receptor function. It enhances NMDA-dependent long-term potentiation in hippocampal CA1 pyramidal cells and attenuates hyperlocomotion induced by psychostimulants (e.g., D-amphetamine) or NMDA receptor glycine site antagonists (e.g., L-687,414) in animal models. It also prevents hyper-responsiveness to D-amphetamine challenge in rats chronically treated with phencyclidine, an NMDA receptor open-channel blocker. By increasing extracellular glycine levels in the striatum and cerebrospinal fluid, Bitopertin (R enantiomer) may serve as a candidate for the treatment of conditions associated with NMDA receptor hypofunction, such as schizophrenia.